Targets for Cancer IO: A Deep Dive Series is supported, in part, by grants from Alkermes, Inc., Genentech, a member of the Roche Group, Incyte Corporation, Merck & Co., Inc., and Regeneron Pharmaceuticals (as of 10/05/2021).
Interested in supporting this program? The SITC Development team would love to work with you. Contact Development@sitcancer.org for more information on how your organization's support can help advance cancer immunotherapy and make "cure" a reality.